Anti-obesity agents
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Kourouniades, Stavros | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2017-08-03T08:06:51Z | |
| dc.date.available | 2017-08-03T08:06:51Z | |
| dc.date.created | 2017 | |
| dc.description.abstract | Obesity is a preventable complex multifactorial disease. With the steady and rapid progression of obesity trends in the past few decades, it has become a global epidemic. The ideal anti-obesity agent is that which will provide a sustained, long term weight loss with minimal side effects. Current and emerging pharmacological treatment options of obesity are closer to the ideal anti-obesity agent, providing exemplary results in weight loss with a minimum amount of side effects. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 33 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/242847 | |
| dc.language.iso | en | hu_HU |
| dc.subject | obesity | hu_HU |
| dc.subject | anti-obesity agents | |
| dc.subject | orlistat | |
| dc.subject | lorcaserin | |
| dc.subject | beloranib | |
| dc.subject | liraglutide | |
| dc.subject | naltrexone/bupropion | |
| dc.subject | phentermine/topiramate | |
| dc.title | Anti-obesity agents | hu_HU |